Victory Capital Management Inc Atea Pharmaceuticals, Inc. Transaction History

Victory Capital Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	BUY	$5.49 - $8.79 $3,837 - $6,144	699 Added 1.67%	42,666 $243,000
Q2 2022 Aug 01, 2022	SELL	$5.33 - $8.18 $10,254 - $15,738	-1,924 Reduced 4.38%	41,967 $298,000
Q1 2022 May 04, 2022	SELL	$5.5 - $9.19 $231,654 - $387,073	-42,119 Reduced 48.97%	43,891 $258,000
Q4 2021 Feb 07, 2022	BUY	$7.67 - $44.59 $599,694 - $3.49 Million	78,187 Added 999.45%	86,010 $769,000
Q3 2021 Nov 02, 2021	BUY	$21.33 - $35.06 $166,864 - $274,274	7,823 New	7,823 $274,000
Q2 2021 Aug 03, 2021	SELL	$19.22 - $59.08 $136,231 - $418,759	-7,088 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$41.42 - $88.44 $293,584 - $626,862	7,088 New	7,088 $438,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.